{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:29:16Z","timestamp":1781332156861,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clinthera.2024.04.002","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T12:41:57Z","timestamp":1714740117000},"page":"455-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiretroviral Stewardship: Top 10 Questions Encountered by Stewardship Teams and Solutions to Optimize Therapy"],"prefix":"10.1016","volume":"46","author":[{"given":"Mei H.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Acbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Nori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.04.002_bib0001","unstructured":"National Institutes of Health. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0002","unstructured":"Cabenuva (Cabotegravir and Rilpivirine) [Prescribing Information]. ViiV healthcare, Durham, NC; 2023."},{"issue":"7","key":"10.1016\/j.clinthera.2024.04.002_bib0003","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.002_bib0004","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2024.04.002_bib0005","article-title":"1582. Real-world use of long-acting cabotegravir + rilpivirine in the US: effectiveness in the first year","volume":"9","author":"Sension","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.clinthera.2024.04.002_bib0006","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2024.04.002_bib0007","unstructured":"National Institutes of Health. Management of the treatment-experienced patient. https:\/\/clinicalinfo.hiv.gov\/sites\/default.files\/guidelines\/documents\/adult-adolescent-arv\/virologic-failure-adult-adolescent-arv.pdf. Accessed March 25, 2024."},{"issue":"11","key":"10.1016\/j.clinthera.2024.04.002_bib0008","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/phar.1835","article-title":"A HAART-breaking review of alternative antiretroviral administration: practical considerations with crushing and enteral tube scenarios","volume":"36","author":"Huesgen","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.002_bib0009","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0148607108330314","article-title":"Enteral nutrition practice recommendations","volume":"33","author":"Bankhead","year":"2009","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"4","key":"10.1016\/j.clinthera.2024.04.002_bib0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1345\/aph.1P599","article-title":"An in-depth analysis of medication errors in hospitalized patients with HIV","volume":"45","author":"Snyder","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.clinthera.2024.04.002_bib0011","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/cid\/ciz792","article-title":"A call to action: the role of antiretroviral stewardship in inpatient practice, a joint policy paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine","volume":"70","author":"Koren","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.clinthera.2024.04.002_bib0012","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2146\/ajhp170420","article-title":"Impact of an antiretroviral stewardship strategy on medication error rates","volume":"75","author":"Shea","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2024.04.002_bib0013","article-title":"Antiretroviral stewardship: a review of published outcomes with recommendations for program implementation","volume":"19","author":"Michienzi","year":"2020","journal-title":"J Int Assoc Prov AIDS Care"},{"issue":"1","key":"10.1016\/j.clinthera.2024.04.002_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/apc.2022.0192","article-title":"Pharmacist-involved antiretroviral stewardship programs in people living with HIV\/AIDS: a systematic review","volume":"37","author":"Ahmed","year":"2023","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.002_bib0015","first-page":"353","article-title":"Customized order-entry sets can prevent antiretroviral prescribing errors: a novel opportunity for antimicrobial stewardship","volume":"40","author":"Guo","year":"2015","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.clinthera.2024.04.002_bib0016","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/cis491","article-title":"Antiretroviral medication errors remain high but are quickly corrected among hospitalized HIV-infected adults","volume":"55","author":"Yehia","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.002_bib0017","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2146\/ajhp110172","article-title":"Implementation of targeted interventions to decrease antiretroviral-related errors in hospitalized patients","volume":"69","author":"Daniels","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.002_bib0018","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/8755122513500919","article-title":"Incidence of antiretroviral drug interactions during hospital course: the role of a pharmacist-led antiretroviral stewardship program","volume":"30","author":"Bias","year":"2014","journal-title":"J Pharm Technol"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.002_bib0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0897190017729599","article-title":"To assess the success of computerized order sets and pharmacy education modules in improving antiretroviral prescribing","volume":"31","author":"Mehta","year":"2018","journal-title":"J Pharm Pract"},{"issue":"7","key":"10.1016\/j.clinthera.2024.04.002_bib0020","doi-asserted-by":"crossref","first-page":"ofz290","DOI":"10.1093\/ofid\/ofz290","article-title":"Impact of an antiretroviral stewardship team on the care of patients with human immunodeficiency virus infection admitted to an academic medical center","volume":"6","author":"DePuy","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.002_bib0021","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1086\/675287","article-title":"Antimicrobial stewardship program to reduce antiretroviral medication errors in hospitalized patients with human immunodeficiency virus infection","volume":"35","author":"Sanders","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7-8","key":"10.1016\/j.clinthera.2024.04.002_bib0022","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1345\/aph.1R773","article-title":"Medication errors in HIV-infected hospitalized patients: a pharmacist's impact","volume":"47","author":"Eginger","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2024.04.002_bib0023","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/ofid\/ofw172.1197","article-title":"Adherence to antiretroviral therapy in hospitalized HIV-positive patients","volume":"3","author":"Decano","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2024.04.002_bib0024","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/ofid\/ofx163.1102","article-title":"Avoiding inpatient delays in antiretroviral therapy via low cost formulary management","volume":"4","author":"Sundquist","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.clinthera.2024.04.002_bib0025","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1016\/S2352-3018(22)00249-1","article-title":"Two-drug regimens for HIV treatment","volume":"9","author":"Gibas","year":"2022","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.clinthera.2024.04.002_bib0026","doi-asserted-by":"crossref","first-page":"ofy225","DOI":"10.1093\/ofid\/ofy225","article-title":"Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment","volume":"5","author":"Fischetti","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.clinthera.2024.04.002_bib0027","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/QAD.0000000000002903","article-title":"Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!","volume":"35","author":"Wood","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2024.04.002_bib0028","unstructured":"Stanford University. HIV drug resistance database. https:\/\/hivdb.stanford.edu. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0029","unstructured":"University of Liverpool. HIV drug interactions. https:\/\/hiv-druginteractions.org\/checker. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0030","unstructured":"HIV-ASSIST, Inc. HIV-ASSIST. https:\/\/www.hivassist.com. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0031","unstructured":"HIV Clinical Care Options. https:\/\/clinicaloptions.com\/CE-CME. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0032","unstructured":"AIDS Education and Training Center Program. AETC National Coordinating Resource Center. https:\/\/aidsetc.org\/. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0033","unstructured":"Office of AIDS Research. ClinicalInfo. https:\/\/clinicalinfo.hiv.gov. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0034","unstructured":"Centers for Disease Control and Prevention. HIV. https:\/\/www.cdc.gov\/hiv\/clinicians\/. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0035","unstructured":"University of California, San Francisco. National Clinician Consultation Center. https:\/\/nccc.ucsf.edu\/. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0036","unstructured":"National AIDS Treatment Advocacy Project (NATAP). https:\/\/www.natap.org. Accessed March 25, 2024."},{"key":"10.1016\/j.clinthera.2024.04.002_bib0037","unstructured":"National Institutes of Health. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/Documents\/perinatal-hiv\/guidelines-perinatal.pdf Accessed March 25, 2024."},{"issue":"9","key":"10.1016\/j.clinthera.2024.04.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019023","article-title":"Values and preferences of women living with HIV who are pregnant, postpartum or considering pregnancy on choice of antiretroviral therapy during pregnancy","volume":"7","author":"Lytvyn","year":"2017","journal-title":"BMJ Open"},{"issue":"18","key":"10.1016\/j.clinthera.2024.04.002_bib0039","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","article-title":"Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group","volume":"331","author":"Connor","year":"1994","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinthera.2024.04.002_bib0040","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/QAD.0b013e3282f9b67a","article-title":"Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006","volume":"22","author":"Townsend","year":"2008","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.002_bib0041","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/hiv.12397","article-title":"HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa","volume":"18","author":"Myer","year":"2017","journal-title":"HIV Med"},{"issue":"6","key":"10.1016\/j.clinthera.2024.04.002_bib0042","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1310\/hct1106-303","article-title":"Italian group on surveillance on antiretroviral treatment in pregnancy. Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy","volume":"11","author":"Floridia","year":"2010","journal-title":"HIV Clin Trials"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.002_bib0043","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/QAI.0000000000001954","article-title":"Does changing antiretroviral therapy in the first trimester of pregnancy for safety concerns have an impact on viral suppression?","volume":"80","author":"Peyronnet","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.clinthera.2024.04.002_bib0044","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/cid\/cit374","article-title":"ANRS-EPF CO1-CO11 Study Group. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?","volume":"57","author":"Briand","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2024.04.002_bib0045","series-title":"12th International AIDS Society Conference on HIV Science","article-title":"Pharmacokinetics, safety and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in virologically suppressed pregnant women with HIV","author":"Zhang","year":"2023"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.002_bib0046","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.13217","article-title":"Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis","volume":"27","author":"Platt","year":"2020","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.clinthera.2024.04.002_bib0047","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/QAD.0b013e328334bddb","article-title":"SMART INSIGHT study group. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption","volume":"24","author":"Dore","year":"2010","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.002_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004196","article-title":"Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: a systematic review and meta-analysis","volume":"20","author":"Yin","year":"2023","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.clinthera.2024.04.002_bib0049","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2024.04.002_bib0050","doi-asserted-by":"crossref","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.002_bib0051","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinthera.2024.04.002_bib0052","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1086\/317535","article-title":"Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy","volume":"32","author":"Manegold","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clinthera.2024.04.002_bib0053","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/595006","article-title":"HIV\/AIDS: immune reconstitution inflammatory syndrome: a reappraisal","volume":"48","author":"French","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2024.04.002_bib0054","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.clinthera.2024.04.002_bib0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4103\/0971-5916.92632","article-title":"HIV & immune reconstitution inflammatory syndrome (IRIS)","volume":"134","author":"Sharma","year":"2011","journal-title":"Indian J Med Res"},{"issue":"6","key":"10.1016\/j.clinthera.2024.04.002_bib0056","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-133-6-200009190-00013","article-title":"Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy","volume":"133","author":"DeSimone","year":"2000","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.clinthera.2024.04.002_bib0057","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinthera.2024.04.002_bib0058","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1473-3099(14)70733-9","article-title":"Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial","volume":"14","author":"Mfinanga","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.002_bib0059","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0b013e328011efac","article-title":"Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa","volume":"21","author":"Lawn","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2024.04.002_sbref0060","series-title":"Management of Immune Reconstitution Inflammatory Syndrome (IRIS) [Internet]","author":"Brust","year":"2021"},{"issue":"16","key":"10.1016\/j.clinthera.2024.04.002_bib0061","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clinthera.2024.04.002_bib0062","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"CAMELIA (ANRS 1295\u2013CIPRA KH001) study team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinthera.2024.04.002_bib0063","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/QAI.0b013e31825b5e06","article-title":"Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study","volume":"60","author":"Manosuthi","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.clinthera.2024.04.002_bib0064","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1086\/652652","article-title":"Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa","volume":"50","author":"Makadzange","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"26","key":"10.1016\/j.clinthera.2024.04.002_bib0065","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"COAT trial team. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","volume":"370","author":"Boulware","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clinthera.2024.04.002_bib0066","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"Meintjes","year":"2010","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.clinthera.2024.04.002_bib0067","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1086\/497269","article-title":"Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up","volume":"41","author":"Phillips","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:30:00Z","timestamp":1726857000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182400081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S014929182400081X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.04.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiretroviral Stewardship: Top 10 Questions Encountered by Stewardship Teams and Solutions to Optimize Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}